Introduction
IL-6 and its receptor
Tocilizumab
Methods
Results
SLE
Juvenile DM
Vasculitis
Authors, year (ref.) | Sex | Age at onset, years | Age at TCZ, years | Manifestations | Previous therapy | Dose of TCZ | Duration of TCZ, months | Adverse effect of TCZ | |
---|---|---|---|---|---|---|---|---|---|
Bravo Mancheno et al., 2012 [38] | F | 3 | 5 | Wall thickening, occlusion | GC, MTX, ETN, IFX, CYC, MMF | 8 mg/kg /2–3 weeks | > 24 | No | |
Batu et al., 2017 [39] | F | 4 | 9 | Stenosis | GC, CYC, MTX, AZA | 8 mg/kg /4 weeks | 7–13 | No | |
F | 13 | 15 | Aneurysms | ||||||
F | 16 | 16 | Graft, stenosis and aneurysms | GC, CYC, MTX | |||||
GC, CYC, ETN | |||||||||
F | 16 | 16 | Wall thickening | GC | |||||
Decker et al., 2018 [40] | F | 13 | 15 | Panaortitis | GC, MTX, IFX | 8 mg/kg /4 weeks | 18 | No | |
Canas et al., 2014 [41] | F | 12 | Wall thickening | GC | 8 mg/kg /4 weeks | 18 | No | ||
F | 14 | Wall thickening | GC, MTX | 12 | |||||
Goel et al., 2013 [42] | F | 13 | 13 | In-stent restenosis | GC, MMF | 8 mg/kg /4 weeks | 6 | No serious AE | |
In-stent restenosis | GC, MMF | ||||||||
F | 14 | 15 |
Scleroderma
Autoimmune encephalitis
Kawasaki’s disease
JIA-associated refractory uveitis
Authors, year (ref.) | Sex | Age at onset, years | Age at TCZ, years | Previous therapy | Dose of TCZ | Efficacy of TCZ | Duration of TCZ | Adverse effect of TCZ |
---|---|---|---|---|---|---|---|---|
Tsang et al., 2014 [60] | M | 3 | 12 | GC, MTX, ADA, RTX | 8 mg/kg/2–4 weeks | Quiescence of uveitis | 20 weeks | Neutropenia when infused every 2 weeks |
Tappeiner et al., 2016 [58] | F:M 14:3 | 15.3 ± 6.9 | GC, MTX, ≥1 TNF-α inhibitor | Inactive in 10, persisted in 7 | 5.7 months | No | ||
Calvo-Rio et al., 2017 [57] | F:M 21:4 | 18.5 ± 8.3 (8–38) | GC, MTX, IFX, ETN, ADA, GLM, ABA, ANK, RTX | 8 mg/kg/2, 4, 8 weeks | Inactive in 19 cases | 5.5–24 months | Thrombocytopenia (1), pneumonia, thrombocytopenia, and hemolytic anemia (1), Viral conjunctivitis and bullous impetigo (1) | |
162 mg/week SC | ||||||||
Quesada-Masachs et al., 2017 [62] | F | 1.9 | 14 | MTX, leflunomide, ADA | 8 mg/kg/month switching to 162 mg/week SC | Ocular flare after 6 months | 6 months | No |
Castleman’s disease
Amyloid a amyloidosis
Cytokine release syndrome
Other autoinflammatory conditions
Grave’s disease
Conclusion
Disease |
n
| Age, years | Efficacy of TCZ | Dose of TCZ | Adverse effect of TCZ | References |
---|---|---|---|---|---|---|
Juvenile SLE | 1 | 13 | Improved arthritis and inflammatory markers Reduction of GC dose | 400 mg/month | No | [21] |
Juvenile dermatomyositis | 1 | 12 | Improved arthritis | 8 mg/kg/4 weeks | No | [28] |
Takayasu arteritis | 12 | 3–16 | Improved symptoms and inflammatory marker Reduction of GC dose No FDG uptake | 8 mg/kg/3–4 weeks | No | |
Juvenile localized scleroderma | 7 | 6–13 | Improved disease activity and inhibition of progression | ≥30 kg: 8 mg/kg < 30 kg: 12 mg/kg every 4 weeks | No | |
Autoimmune encephalitis | 3 | 10, 12, 15 | Improved neurological symptoms without recurrence | 8–12 mg/kg/4 weeks | No | [51] |
Kawasaki’s disease | 4 | 1–8 | Improved symptoms and inflammatory markers | 8 mg/kg once | Giant coronary artery aneurysm (2) | [55] |
JIA-associated uveitis | 8–38 | Improved visual acuity Reduction of GC dose | 8 mg/kg/4 weeks | Thrombocytopenia (1), pneumonia, thrombocytopenia, and hemolytic anemia (1), viral conjunctivitis and bullous impetigo (1) | ||
Multicentric Castleman’s disease | 4 | 1–16 | Sustained remission | 8 mg/kg/2 weeks 10 mg/kg three times 8 mg/kg/2 weeks | Herpes zoster (1) | |
Amyloid A amyloidosis | 3 | 19, 26, 29 | Improved symptoms and inflammatory markers | 8 mg/kg/2–4 weeks | No | |
Cytokine release syndrome (CRS) | 15 | 7–16 | Improved symptoms and inflammatory markers | 8 mg/kg 1–3 times | No | |
Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) | 1 | 4 | Improved symptoms and inflammatory markers | 8 mg/kg/month | No | [74] |
H syndrome (PHID) | 4 | 3–19 | Improved symptoms and inflammatory markers | IV: 8 mg/kg SQ: 10.8–12 mg/kg every 2 weeks | No | |
Undifferentiated autoinflammatory disease with interstitial pneumonitis | 1 | 15 | Improved symptoms and reduction of ground-glass opacity on CT | 8 mg/kg/month | No | [78] |